Dye, John M.
Wu, Hua
Hooper, Jay W.
Khurana, Surender
Kuehne, Ana I.
Coyle, Elizabeth M.
Ortiz, Ramon A.
Fuentes, Sandra
Herbert, Andrew S.
Golding, Hana
Bakken, Russell A.
Brannan, Jennifer M.
Kwilas, Steve A.
Sullivan, Eddie J.
Luke, Thomas C.
Smith, Gale
Glenn, Gregory
Li, Wenfang
Ye, Ling
Yang, Chinglai
Compans, Richard W.
Tripp, Ralph A.
Jiao, Jin-an
Article History
Received: 1 October 2015
Accepted: 7 April 2016
First Online: 25 April 2016
Competing interests
: Authors from SAB Biotherapeutics, Inc. and Novavax, Inc were employees of these for-profit organizations at the time of the study and authors from these organizations have financial interests in their respective companies. The authors also have submitted patent applications related to the work which are pending. The authors have developed a lead candidate therapeutic antibody (SAB-139) from this work, which would be considered a product of the company intended for further development as a commercial venture. This does not alter the authors’ adherence to policies on sharing data and materials.